Search results
Results From The WOW.Com Content Network
Dutasteride is approved for the treatment of male androgenetic alopecia in South Korea and Japan at a dosage of 0.5 mg per day. [6] [17] Several studies have found it to induce hair regrowth in men more rapidly and to a greater extent than even the highest approved dosage of finasteride.
It is a combination of two previously existing medications: dutasteride, brand name Avodart, and tamsulosin, brand name Flomax. It contains 0.5 mg of dutasteride and 0.4 mg of tamsulosin hydrochloride. [2] Jalyn was the result of the CombAT (Combination of Avodart and Tamsulosin) trial of 2008.
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
Estradiol valerate is and has been available in the form of vials and ampoules of oil solution for intramuscular injection in concentrations of 4, 5, 10, 20, and 40 mg/mL and in the form of oral tablets at doses of 0.5, 1, 2, and 4 mg per tablet.
1,25 dihydroxycholecalciferol 1-Day 1-deamino-8-d-arginine vasopressin 13-cis-retinoic acid 2'-deoxycoformycin 2-amino-6-mercaptopurine 2-amino-6-trifluoromethoxy-benzothiazole 2-CdA 2-chlorodeoxyadenosine 2-PAM 2-propylpentanoic acid 2-propylvaleric acid 2-pyridine aldoxime methochloride 292 MEP 311C90 3M Avagard (Discontinued) 3M Cavilon Skin ...
Flomax 0.4 mg oral capsule. Tamsulosin is primarily used for benign prostatic hyperplasia (BPH) and to help with the passage of kidney stones. [13] [14] Tamsulosin, however, appears to be effective only for stones over 4 mm and less than 10 mm in size. [8] Tamsulosin is also used as an add-on treatment for acute urinary retention. People may ...
Estradiol/dydrogesterone (E2/DYD), sold under the brand name Femoston among others, is a combination of estradiol (E2), an estrogen, and dydrogesterone (DYD), a progestin, which is used in menopausal hormone therapy, specifically to treat and prevent hot flashes and osteoporosis, in postmenopausal women.
Another large study reported a rate of impotence of only 9.3% with bicalutamide relative to 6.5% for standard care (the controls), a rate of decreased libido of only 3.6% with bicalutamide relative to 1.2% for standard care, and a rate of 9.2% with bicalutamide for hot flashes relative to 5.4% for standard care. [125]